Company / Cash & Equivalents
OMEROS CORP Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.4M
FY2024
5-year range
$3.4M / $100.8M
FY2020-FY2024
Trend
-52.1%
vs FY2023
Sector context
#206 of 207
Health Care
What the data says
Among 207 Health Care companies, OMEROS CORP is in the bottom 0% for cash & equivalents. Cash & Equivalents has declined for 3 consecutive years, from $101M in FY2021 to $3M in FY2024.
Based on SEC 10-K filings.
$3M in FY2024 with a 5-year CAGR of +2.0%.
Declined from $11M to $3M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -67.7%
- 5-Year CAGR
- +2.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 207This company $3.4M Sector average $669.5M
▼
-99.5% below sector average
Key checks
Key Insights
- OMEROS CORP's cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of +2.0%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 52.1% year-over-year.
- Ranks #206 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.92 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $3.4M | -52.1% |
| FY2023 | $7.1M | -35.5% |
| FY2022 | $11.0M | -89.1% |
| FY2021 | $100.8M | +860.0% |
| FY2020 | $10.5M | +240.5% |
| FY2019 | $3.1M | -47.4% |
| FY2018 | $5.9M | +72.7% |
| FY2017 | $3.4M | +52.6% |
| FY2016 | $2.2M | +60.7% |
| FY2015 | $1.4M | +291.0% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026